Ask Warren

JONBUR Research · Update note

You're reading an earlier report from Oct 20, 2026. See the latest report

Yuhan · 000100 · Biotech & Pharma

Yuhan Shares Rise 21.4% in Five Trading Days on Heavy Volume

Why this report

Written after:

  • Big price moveShares up 21.4% over 5 trading days on 2.2× normal volumeOct 19, 2026

Yuhan's shares rose 21.4% over five trading days to 2026-10-19 on 2.2× normal volume, closing at ₩87,400. The move lifts the multiples, but no new filing explains it and the earnings picture in the previous report is unchanged.

Written Oct 20, 2026 · Data as of Oct 19, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

What happened

Starting from 2026-10-13, the day of our previous report, the shares gained 21.4% over five trading days, with volume at 2.2× normal. The close on 2026-10-19 was ₩87,400, versus ₩72,000 on 2026-10-12. Market capitalisation is about ₩6.4T. The one-month return is 15.2%, the three-month return is 26.3% and the one-year return is still -25.1%. The price is 32.4% below its 52-week high of ₩129,200 and 34.5% above the low of ₩65,000.

No filings in the period explain the move. The most recent filings are insider shareholding reports and two supply contract filings in September, and no excerpts were available. News headlines from 2026-10-16 mention an IBK Securities note that cut its target price from ₩160,000 to ₩110,000 because of a valuation method change, expectations of a roughly 30% jump in royalties on a lung cancer drug, and attention on an allergy treatment technology transfer. These are press reports; we cannot confirm them as the cause of the rise. Edaily also described Yuhan as one of few risers on a day when only 21 of 253 bio stocks gained.

Over the last 20 days foreign investors were net buyers of ₩29.3B and institutions of ₩29.9B, while retail investors were net sellers of ₩58.3B. Foreign ownership is 21.5%, up from 19.3% sixty days ago. Short balance is 2.1% of shares.

Every earlier JONBUR Research report and update note on Yuhan, with Pro.

Unlock with Pro

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

Report history

  1. Oct 28, 2026Update noteEarningsYuhan Q3 2026 Preliminary Results: Operating Profit Up 44.2% but Down 43.4% From Q2
  2. Oct 20, 2026Update noteBig price moveYuhan Shares Rise 21.4% in Five Trading Days on Heavy Volume
  3. Oct 13, 2026InitiationYuhan: Profits Recover From a Low Base as the Shares Fall 40.3% Over One Year

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information